HDL and arteriosclerosis: beyond reverse cholesterol transport.
By J. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, A. von Eckardstein. Atherosclerosis, 2002
623 citations recorded by the source corpus.
Subfields: Clinical Biochemistry, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/72074b56f469b3a0591e9052abd529e3634ad1ae
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. (2004, background): “Several functional activities associated with HDL and apoA-I are believed to promote these beneficial effects, including both facilitation of reverse cholesterol transport and additional cardioprotective antioxidant and antiinflammatory functions (49, 68, 69).”
- Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “However, compelling evidence has emerged that additional dimensions of the antiatherogenic action of HDL may be of major physiological and pathological relevance (Nofer et al., 2002; Assmann and Nofer, 2003; Assmann and Gotto, 2004; Navab et al., 2004b).”